Published on 18 Jun 2024 on Insider Monkey · via Yahoo Finance
AtriCure (ATRC) Stock Slipped on Competition Threat
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned 5.77% (net), compared to a 7.58% return for the Russell 2000 Growth Index. Despite a decline in many equity markets in January, they rebounded over the following two months, resulting in a robust 2024 first quarter. In addition, please check the fund’s top five holdings to know its best picks in 2024.
TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks like AtriCure, Inc. (NASDAQ:ATRC), in the first quarter 2024 investor letter. AtriCure, Inc. (NASDAQ:ATRC) develops devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers. The one-month return of AtriCure, Inc. (NASDAQ:ATRC) was 2.48%, and its shares lost 50.36% of their value over the last 52 weeks. On June 20, 2024, AtriCure, Inc. (NASDAQ:ATRC) stock closed at $23.76 per share with a market capitalization of $1.15 billion.